Abstract
The development of anti-inflammatory drugs has witnessed significant advancements, offering new hope for patients suffering from chronic inflammatory diseases such as rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease. This article reviews the current state of research in anti-inflammatory drug development, focusing on the various classes of drugs, including traditional nonsteroidal anti-inflammatory drugs (NSAIDs), biologics, and novel small-molecule inhibitors. In particular, the article highlights the role of cytokine modulation, immune cell targeting, and metabolic pathways in reducing inflammation. Additionally, it provides insights into the ongoing challenges in drug development, such as off-target effects, resistance, and the need for personalized therapies. Recent breakthroughs in precision medicine and nanotechnology are also discussed, shedding light on promising future directions for anti-inflammatory treatments.
All articles published in the American Journal of Pharmaceutics are open access and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows users to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given, a link to the license must be provided, and any changes must be indicated.
-
Authors retain full copyright of their work.
-
The journal does not restrict reuse of content, provided proper citation of the original publication is made.